Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Individualized tissue-engineered veins as vascular grafts: a proof of concept study in pig.
RISE Research Institutes of Sweden, Materials and Production, Chemistry, Biomaterials and Textiles. University of Gothenburg, Sweden.ORCID iD: 0000-0002-4270-8475
VERIGRAFT AB, Sweden.
RISE Research Institutes of Sweden, Materials and Production, Chemistry, Biomaterials and Textiles.
VERIGRAFT AB, Sweden.
Show others and affiliations
2021 (English)In: Journal of Tissue Engineering and Regenerative Medicine, ISSN 1932-6254, E-ISSN 1932-7005, Vol. 15, no 10, p. 818-Article in journal (Refereed) Published
Abstract [en]

Personalized tissue engineered vascular grafts are a promising advanced therapy medicinal product (ATMP) alternative to autologous or synthetic vascular grafts utilized in blood vessel bypass or replacement surgery. We hypothesized that an individualized tissue engineered vein (P-TEV) would make the body recognize the transplanted blood vessel as autologous, decrease the risk of rejection and thereby avoid lifelong treatment with immune suppressant medication as is standard with allogenic organ transplantation. To individualize blood vessels, we decellularized vena cava from six deceased donor pigs and tested them for cellular removal and histological integrity. A solution with peripheral blood from the recipient pigs was used for individualized reconditioning in a perfusion bioreactor for seven days prior to transplantation. To evaluate safety and functionality of the individualized vascular graft in vivo, we transplanted reconditioned porcine vena cava into six pigs and analyzed histology and patency of the graft at different time points, with three pigs at the final endpoint 4-5 weeks after surgery. Our results showed that the P-TEV was fully patent in all animals, did not induce any occlusion or stenosis formation and we did not find any signs of rejection. The P-TEV showed rapid recellularization in vivo with the luminal surface covered with endothelial cells. In summary, the results indicate that P-TEV is functional and have potential for use as clinical transplant grafts. 

Place, publisher, year, edition, pages
2021. Vol. 15, no 10, p. 818-
Keywords [en]
ATMP, Blood vessels, Recellularization, Regenerative medicine, Scaffold, Tissue engineering, decellularization, recellularization, tissue engineering, vascular grafts
National Category
Surgery
Identifiers
URN: urn:nbn:se:ri:diva-55773DOI: 10.1002/term.3233PubMedID: 34318614OAI: oai:DiVA.org:ri-55773DiVA, id: diva2:1583598
Available from: 2021-08-09 Created: 2021-08-09 Last updated: 2023-06-07Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Håkansson, JoakimPetronis, Sarunas

Search in DiVA

By author/editor
Håkansson, JoakimPetronis, Sarunas
By organisation
Chemistry, Biomaterials and Textiles
In the same journal
Journal of Tissue Engineering and Regenerative Medicine
Surgery

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 40 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf